Other languages Keymed Biosciences Inc.

Equities

2162

KYG5252B1023

Market Closed - Hong Kong S.E. Other stock markets 01:38:20 26/04/2024 pm IST			5-day change	1st Jan Change
34.9 ^HKD	-0.14%		+27.14%	-28.92%

12/04	Keymed Biosciences Advances Solid Tumors Drug With First Patient Study	MT
27/03	KeyMed Biosciences’ Attributable Loss Widens in 2023	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Keymed Biosciences Advances Solid Tumors Drug With First Patient Study	12/04
KeyMed Biosciences’ Attributable Loss Widens in 2023	27/03
Keymed Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Keymed Biosciences Buys Back Shares	22/01
Keymed Biosciences Inc. Announces Phase III Clinical Trial of Cm310 for the Treatment of Chronic Rhinosinusitis with Nasal Polyps	27/12
Keymed Biosciences Inc. Announces New Drug Application of Stapokibart Injection	07/12
Keymed Biosciences Inc. Announces the Latest Data from a Phase I Clinical Study of CMG901	08/11
Keymed Biosciences Inc. Announces CM310 Phase III Clinical Trial Topline Data Accepted for Poster Presentation at the European Academy of Dermatology and Venereology Congress 2023	11/23/11
Keymed Biosciences’ Profit Surges in H1	25/23/25
Keymed Biosciences Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	24/23/24
Keymed Biosciences Inc. Announces Latest Data from the Phase I Clinical Study of CM313	12/23/12
Keymed Biosciences Inc. Announces Latest Development on Phase III Clinical Trial of CM310 for the Treatment of Moderate to Severe Atopic Dermatitis in Adults	30/23/30
Keymed Biosciences Inc. Announces Board and Committee Changes	17/23/17
Stocks add to rebound; SSE ups earnings guidance	30/23/30
Keymed Biosciences Inc. Announces Phase III Confirmatory Clinical Study of Its Self-Developed Class 1 Innovative Drug CM310 Recombinant Humanized Monoclonal Antibody Injection	28/23/28
Keymed Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	17/23/17
InnoCare and Keymed Jointly Announce First Subject Dosed in Clinical Trial of CCR8 Monoclonal Antibody ICP-B05	24/23/24
AstraZeneca : accord de licence exclusif avec KYM Biosciences	23/23/23
Keymed and Lepu Biopharma Jointly Announces Global Exclusive Licence Agreement with Astrazeneca for Cmg901	23/23/23
Keymed Biosciences Inc. Announces Latest Results from the Phase Ia Clinical Study of CMG901 at the 2023 ASCO GI CANCERS SYMPOSIUM	18/23/18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Keymed Biosciences Inc.

Equities

2162

KYG5252B1023

Other languages

Filters